November 16, 2016 - By Winifred Garcia · 0 Comments
Biodel Inc (NASDAQ:BIOD) institutional sentiment increased to 0.64 in 2016 Q2. Its up 0.14, from 0.5 in 2016Q1. The ratio improved, as 7 investment managers increased and started new equity positions, while 11 cut down and sold their holdings in Biodel Inc. The investment managers in our partner’s database reported: 5.68 million shares, down from 7.05 million shares in 2016Q1. Also, the number of investment managers holding Biodel Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 5 Increased: 6 New Position: 1.
Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.25 billion. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. It currently has negative earnings. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate.
The stock closed at $19.46 during the last session. It is down 80.56% since April 4, 2016 and is uptrending. It has outperformed by 75.87% the S&P500.
Analysts await Albireo Pharma Inc (NASDAQ:BIOD) to report earnings on December, 15.
Acadian Asset Management Llc holds 0% of its portfolio in Albireo Pharma Inc for 37,389 shares. Ameriprise Financial Inc owns 12,300 shares or 0% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 746 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Blackrock Institutional Trust Company N.A., a California-based fund reported 25,914 shares.#img1#
Ratings analysis reveals 0 of Biodel’s analysts are positive. Out of 2 Wall Street analysts rating Biodel, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. BIOD was included in 2 notes of analysts from December 18, 2015. The company was downgraded on Friday, December 18 by William Blair. The stock of Albireo Pharma Inc (NASDAQ:BIOD) has “Neutral” rating given on Friday, December 18 by Ladenburg Thalmann.
More notable recent Albireo Pharma Inc (NASDAQ:BIOD) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016, also Streetinsider.com with their article: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” published on November 07, 2016, Marketwired.com published: “Biodel Inc. and Albireo Limited Agree to Combine” on May 25, 2016. More interesting news about Albireo Pharma Inc (NASDAQ:BIOD) were released by: Globenewswire.com and their article: “Albireo’s Lead Product Candidate for Orphan Pediatric Liver Disease Accepted …” published on November 15, 2016 as well as Bostonglobe.com‘s news article titled: “Boston biotech Albireo goes public in unusual fashion” with publication date: November 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia